Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Combinations in Advanced Clear Cell Renal Cell Carcinoma
NCT07877194Phase 2Not yet recruiting
- Sponsor
- Summit Therapeutics
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 2
01
Overview
A Phase 2 trial of ivonescimab in clear cell renal cell carcinoma (ccRCC), sponsored by Summit Therapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07877194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877194.